Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study

Inclusion criteria

• Patient over 18 years
• Inpatient orthopedic surgery
• Achieved a bone and joint infection documented gram + (staphylococci golden coagulase-negative staphylococci, enterococci, streptococci)
• Bacteria resistant to lincosamides, quinolones and rifampicin
• Bacteria susceptible to teicoplanin (MIC ≤ 4 mg / L)
• Balanced patient teicoplanin administered intravenously (2 successive doses between 30 and 40 mg / mL)

Exclusion criteria

• Patient not affiliated to the social security
• Pregnant and lactating women
• Known hypersensitivity to teicoplanin (rash, ...)
• Patients with a central catheter or an implantable chamber
• Patient hemodialysis
• Patient has another participant biomedical research on a drug to prevent drug interactions
• Patient minor
• Patient major protected (protection of the court, wardship, trusteeship)
• Patient admitted for emergency or incapable of consent